BioStreet(TM) Appoints Roger Longman to Board of Directors

Apr 24, 2001, 01:00 ET from BioStreet

    SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire Interactive News
 Release/ -- BioStreet(TM), the premier life sciences partnering company, today
 announced the appointment of Roger Longman to its Board of Directors.
 BioStreet also announced that Srini Akkaraju, M.D., Ph.D. is leaving the
 Board.  The Company now has five Board members.
     Mr. Longman, age 46, has 17 years of research and editorial experience in
 the pharmaceutical and biotechnology industry.  He currently is a managing
 partner and editor at Windhover Information Inc., the leading provider of
 strategic business information for pharmaceutical and medical device companies
 and publisher of "IN VIVO: The Business Medical Report" and "START-UP:
 Windhover's Review of Emerging Medical Ventures" as well as the "Strategic
 Transactions" database of industry M&A, alliances and financings.
     "It is with great enthusiasm that I join BioStreet's board of directors,"
 said Roger Longman, Windhover Information's managing partner and editor.
 "Over the last few years, especially with the advent of the genomics era, it
 has become more and more clear that if pharmaceutical and biotech companies
 want to fully realize the benefits of dealmaking, they must first improve the
 infrastructure of the deal.
     "The days of poring over scientific data with the hope of identifying a
 hot deal are over.  Traveling across the United States and around the world
 for a handful of meetings that often miss the mark have passed.  With
 BioStreet, we expect high-quality deals to be identified, researched and
 negotiated more swiftly and cost-effectively, so dealmakers and companies can
 experience much better results," continued Longman.
     Mr. Longman and his partner David Cassak started Windhover Information in
 1989.  Since its inception, the company has been dedicated to providing
 superior analysis and commentary on health care business strategy, industry
 dealmaking, and marketplace trends.  In the process its editorial and research
 staff have amassed incomparable expertise and data on issues impacting the
 healthcare industry.
     "With 12 years experience managing Windhover Information, Roger brings
 vast experience running an information-driven business, which we expect will
 greatly enhance the products and services offered by BioStreet," said Dick
 Haiduck, BioStreet's president and chief executive officer.  "With his
 appointment, we have a Board composed of leading industry figures who
 represent various dealmaking and industry interests, all of which will serve
 to guide BioStreet's mission and commitment to the reinvention of life
 sciences dealmaking."
     Mr. Longman holds a Bachelor's degree from Cornell University and a
 Master's degree from the University of North Carolina, Chapel Hill.  Before
 starting Windhover, he spent six years with The Wilkerson Group, a health care
 industry consulting firm.
     BioStreet's Board of Directors also includes Ron Eastman, Chairman of the
 Board and Chief Executive Officer, EdeNET Communications, Inc.; Nick Simon,
 Chief Executive Officer, Collabra Pharma; Steve Burrill, Chief Executive
 Officer, Burrill & Company; and Stephen Evans-Freke, most recently the
 Chairman and Chief Executive Officer of Sugen, Inc.
 
     BioStreet - Better Deals, Done Sooner
     BioStreet is committed to reinventing the partnering process for both
 sellers and buyers in the life sciences industry by providing solutions that
 enable clients to achieve better deals, done sooner.  Its lead products,
 DealXchange, an online marketplace exchange, and DealXpert(TM), an online due
 diligence resource based on Windhover taxonomy and content and currently under
 development, have been designed to establish new industry standards and
 processes for identifying and assessing partnering opportunities.  The Company
 promotes quality control of its scientific and business listings through
 consultative review by BioStreet's scientific staff and advisors.  BioStreet
 is privately held and based in South San Francisco.  For a demonstration and
 more information, visit the company's web site at www.BioStreet.com or call
 650-246-8775.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X87852358
 
 

SOURCE BioStreet
    SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire Interactive News
 Release/ -- BioStreet(TM), the premier life sciences partnering company, today
 announced the appointment of Roger Longman to its Board of Directors.
 BioStreet also announced that Srini Akkaraju, M.D., Ph.D. is leaving the
 Board.  The Company now has five Board members.
     Mr. Longman, age 46, has 17 years of research and editorial experience in
 the pharmaceutical and biotechnology industry.  He currently is a managing
 partner and editor at Windhover Information Inc., the leading provider of
 strategic business information for pharmaceutical and medical device companies
 and publisher of "IN VIVO: The Business Medical Report" and "START-UP:
 Windhover's Review of Emerging Medical Ventures" as well as the "Strategic
 Transactions" database of industry M&A, alliances and financings.
     "It is with great enthusiasm that I join BioStreet's board of directors,"
 said Roger Longman, Windhover Information's managing partner and editor.
 "Over the last few years, especially with the advent of the genomics era, it
 has become more and more clear that if pharmaceutical and biotech companies
 want to fully realize the benefits of dealmaking, they must first improve the
 infrastructure of the deal.
     "The days of poring over scientific data with the hope of identifying a
 hot deal are over.  Traveling across the United States and around the world
 for a handful of meetings that often miss the mark have passed.  With
 BioStreet, we expect high-quality deals to be identified, researched and
 negotiated more swiftly and cost-effectively, so dealmakers and companies can
 experience much better results," continued Longman.
     Mr. Longman and his partner David Cassak started Windhover Information in
 1989.  Since its inception, the company has been dedicated to providing
 superior analysis and commentary on health care business strategy, industry
 dealmaking, and marketplace trends.  In the process its editorial and research
 staff have amassed incomparable expertise and data on issues impacting the
 healthcare industry.
     "With 12 years experience managing Windhover Information, Roger brings
 vast experience running an information-driven business, which we expect will
 greatly enhance the products and services offered by BioStreet," said Dick
 Haiduck, BioStreet's president and chief executive officer.  "With his
 appointment, we have a Board composed of leading industry figures who
 represent various dealmaking and industry interests, all of which will serve
 to guide BioStreet's mission and commitment to the reinvention of life
 sciences dealmaking."
     Mr. Longman holds a Bachelor's degree from Cornell University and a
 Master's degree from the University of North Carolina, Chapel Hill.  Before
 starting Windhover, he spent six years with The Wilkerson Group, a health care
 industry consulting firm.
     BioStreet's Board of Directors also includes Ron Eastman, Chairman of the
 Board and Chief Executive Officer, EdeNET Communications, Inc.; Nick Simon,
 Chief Executive Officer, Collabra Pharma; Steve Burrill, Chief Executive
 Officer, Burrill & Company; and Stephen Evans-Freke, most recently the
 Chairman and Chief Executive Officer of Sugen, Inc.
 
     BioStreet - Better Deals, Done Sooner
     BioStreet is committed to reinventing the partnering process for both
 sellers and buyers in the life sciences industry by providing solutions that
 enable clients to achieve better deals, done sooner.  Its lead products,
 DealXchange, an online marketplace exchange, and DealXpert(TM), an online due
 diligence resource based on Windhover taxonomy and content and currently under
 development, have been designed to establish new industry standards and
 processes for identifying and assessing partnering opportunities.  The Company
 promotes quality control of its scientific and business listings through
 consultative review by BioStreet's scientific staff and advisors.  BioStreet
 is privately held and based in South San Francisco.  For a demonstration and
 more information, visit the company's web site at www.BioStreet.com or call
 650-246-8775.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X87852358
 
 SOURCE  BioStreet